Table 3.
Results of base case NMA: Difference in intervention versus the comparator for CFB in SGRQ total score at 6 months, 95% credible intervals, and probability that the intervention is better than the comparator
| Intervention |
Comparator |
||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | TIO 18 | SAL 50 | FOR 12 | TIO 5 | IND 150 | IND 300 | GPM 50 | ||||||||||
| PLACEBO |
estimate |
0.00 |
2.63 |
1.31 |
2.58 |
2.21 |
3.87 |
3.57 |
3.18 |
||||||||
| 95% CrI |
|
|
1.91 |
3.31 |
0.48 |
2.21 |
0.60 |
4.53 |
0.78 |
3.61 |
2.56 |
5.17 |
2.30 |
4.84 |
1.78 |
4.56 |
|
| P(better) |
|
|
<1% |
<1% |
1% |
<1% |
<1% |
<1% |
<1% |
||||||||
| TIO 18 |
estimate |
−2.63 |
0.00 |
−1.32 |
−0.05 |
−0.42 |
1.24 |
0.94 |
0.55 |
||||||||
| 95% CrI |
−3.31 |
−1.91 |
|
|
−2.32 |
−0.21 |
−2.09 |
2.01 |
−1.98 |
1.17 |
−0.15 |
2.63 |
−0.41 |
2.31 |
−0.92 |
2.04 |
|
| P(better) |
>99% |
|
|
99% |
52% |
72% |
4% |
8% |
22% |
||||||||
| SAL 50 |
estimate |
−1.31 |
1.32 |
0.00 |
1.27 |
0.91 |
2.56 |
2.26 |
1.87 |
||||||||
| 95% CrI |
−2.21 |
−0.48 |
0.21 |
2.32 |
|
|
−0.92 |
3.36 |
−0.82 |
2.50 |
1.03 |
4.00 |
0.74 |
3.75 |
0.21 |
3.44 |
|
| P(better) |
>99% |
1% |
|
|
12% |
13% |
<1% |
<1% |
1% |
||||||||
| FOR 12 |
estimate |
−2.58 |
0.05 |
−1.27 |
0.00 |
−0.37 |
1.30 |
1.00 |
0.61 |
||||||||
| 95% CrI |
−4.53 |
−0.60 |
−2.01 |
2.09 |
−3.36 |
0.92 |
|
|
−2.78 |
2.05 |
−0.97 |
3.56 |
−0.96 |
2.98 |
−1.81 |
3.02 |
|
| P(better) |
99% |
48% |
88% |
|
|
62% |
13% |
16% |
31% |
||||||||
| TIO 5 |
estimate |
−2.21 |
0.42 |
−0.91 |
0.37 |
0.00 |
1.67 |
1.36 |
0.97 |
||||||||
| 95% CrI |
−3.61 |
−0.78 |
−1.17 |
1.98 |
−2.50 |
0.82 |
−2.05 |
2.78 |
|
|
−0.29 |
3.58 |
−0.53 |
3.26 |
−1.01 |
2.94 |
|
| P(better) |
>99% |
28% |
87% |
38% |
|
|
4% |
7% |
15% |
||||||||
| IND 150 |
estimate |
−3.87 |
−1.24 |
−2.56 |
−1.30 |
−1.67 |
0.00 |
−0.30 |
−0.70 |
||||||||
| 95% CrI |
−5.17 |
−2.56 |
−2.63 |
0.15 |
−4.00 |
−1.03 |
−3.56 |
0.97 |
−3.58 |
0.29 |
|
|
−1.82 |
1.24 |
−2.59 |
1.28 |
|
| P(better) |
>99% |
96% |
>99% |
87% |
96% |
|
|
65% |
77% |
||||||||
| IND 300 |
estimate |
−3.57 |
−0.94 |
−2.26 |
−1.00 |
−1.36 |
0.30 |
0.00 |
−0.39 |
||||||||
| 95% CrI |
−4.84 |
−2.30 |
−2.31 |
0.41 |
−3.75 |
−0.74 |
−2.98 |
0.96 |
−3.26 |
0.53 |
−1.24 |
1.82 |
|
|
−2.28 |
1.47 |
|
| P(better) |
>99% |
92% |
>99% |
84% |
93% |
35% |
|
|
66% |
||||||||
| GPM 50 | estimate |
−3.18 |
−0.55 |
−1.87 |
−0.61 |
−0.97 |
0.70 |
0.39 |
0.00 |
||||||||
| 95% CrI |
−4.56 |
−1.78 |
−2.04 |
0.92 |
−3.44 |
−0.21 |
−3.02 |
1.81 |
−2.94 |
1.01 |
−1.28 |
2.59 |
−1.47 |
2.28 |
|
|
|
| P(better) | >99% | 78% | 99% | 69% | 85% | 23% | 34% | ||||||||||
95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; CFB = Change from baseline; FOR 12 = Formoterol 12 μg twice daily (BID); GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; SAL 50 = Salmeterol 50 μg BID; SGRQ = St. George’s Respiratory Questionnaire; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.